AR 08

Drug Profile

AR 08

Alternative Names: AR-08

Latest Information Update: 22 Mar 2016

Price : $50

At a glance

  • Originator Arbor Pharmaceuticals
  • Class
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Psychiatric disorders

Highest Development Phases

  • Phase II Attention-deficit hyperactivity disorder
  • Suspended Vasomotor symptoms

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 11 Feb 2015 Arbor Pharmaceuticals terminates a phase II trial in Vasomotor symptoms in USA (NCT02049164)
  • 01 Feb 2015 Arbor Pharmaceuticals completes a phase II trial in Attention-deficit hyperactivity disorder (In children, adolescents) in USA (NCT01876719)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top